This is a working overview of cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-29. Anything still debated is marked as such rather than presented as settled.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
=== Polymerization === The polymer formed by linking thiophene through its 2,5 positions is called polythiophene. Polymerization is conducted by oxidation using electrochemical methods (electropolymerization) or electron-transfer reagents. An idealized equation is shown:
government had not publicly announced any contract awards for the Golden Dome, though the Wall Street Journal has reported that SpaceX is "set to receive" a $2 billion contract to build a 600-satellite constellation for missile targeting. This came after Musk's earlier denials of involvement, saying he was focused on Mars. Much smaller contracts for space-based interceptors were reportedly awarded "in secret" in late November. Awardees include Anduril Industries, Lockheed Martin, Northrop Grumman, and True Anomaly (a firm backed by JD Vance venture capital). In December, more than 1,000 "qualifying offerors" were deemed eligible for future awards. In March 2026, Guetlein said the official cost estimate had risen $10 billion, from $175 billion to $185 billion, because “We were asked to procure some additional space capabilities".
Structural similarities between acetyl-CoA and malonyl-CoA suggest that certain lysine acetyltransferases (KATs) may also catalyze malonylation. KAT2A (GCN5) has been experimentally linked to histone malonylation and is currently the strongest candidate, while p300 has also been proposed and is known to mediate other acyl modifications such as crotonylation. Analogous to the GCN5 acetylation mechanism, the ε-amino group is thought to be transiently deprotonated by a catalytic base within the enzyme's active site, thereby enabling the same reaction with malonyl-CoA as in non-enzymatic malonylation. However, specific enzymes known as malonyltransferases have not yet been definitively identified. The demalonylation is catalyzed by the enzyme Sirtuin 5 (SIRT5), a class III histone deacetylase that requires NAD+ for activity but is inhibited by nicotinamide. SIRT5 is globally expressed in mitochondrial, cytoplasmic, and nuclear compartments, and can also remove other negatively charged acyl modifications. It catalyzes the demalonylation in the following reaction:
Theriac or theriaca is a medical concoction originally labelled by the Greeks in the 1st century AD and widely adopted in the ancient world as far away as Persia, China and India via the trading links of the Silk Route. It was an alexipharmic, or antidote for a variety of poisons and diseases. It was also considered a panacea, a term for which it could be used interchangeably: in the 16th century Adam Lonicer wrote that garlic was the rustic's theriac or Heal-All. The word theriac comes from the Greek term θηριακή (thēriakē), a feminine adjective signifying "pertaining to animals", from θηρίον (thērion), "wild animal, beast". The ancient bestiaries included information—often fanciful—about dangerous beasts and their bites. When cane sugar was an exotic Eastern commodity, the English recommended the sugar-based treacle as an antidote against poison, originally applied as a salve. By extension, treacle could be applied to any healing property: in the Middle Ages the treacle (i.e. healing) well at Binsey was a place of pilgrimage. Norman Cantor observes that the remedy's supposed effect followed the homeopathic principle of "the hair of the dog", whereby a concoction containing some of the poisonous (it was thought) flesh of the serpent would be a sovereign remedy against the creature's venom: in The Book of Holy Medicines, Henry of Grosmont, 1st Duke of Lancaster, wrote that "the treacle is made of poison so that it can destroy other poisons".
== Approved drugs == Tissue plasminogen activator (also known as tPA, t-PA, rtPA, Activase, or Alteplase or Actilyse) is a drug that breaks down blood clots. It was first approved in 1996, yet this drug has no generic competition. US sales of the drug under the brand name Activase and a similar drug were approximately US$1.3 billion in 2021, while European sales under the brand name Actilyse were an additional 448 million Euro in 2019. Edaravone (radicut) was approved in Japan in 2001. It has an unknown mechanism of action, but is hypothesized to act through its antioxidant properties.
Sources: en.wikipedia.org
Because many risk factors for addiction are social and modifiable, prevention strategies that target them can improve outcomes; when delivered during childhood and adolescence, such strategies reduce the risk of later substance use disorder. Prevention is usually organized in three tiers: universal programs aimed at a whole population, selective programs aimed at groups at raised risk, and indicated programs aimed at individuals already showing early signs of problem use. Interventions with the strongest evidence include family skills programs, personal and social skills education delivered in schools, and policies that limit availability and raise the price of alcohol and tobacco. Programs based on information provision alone, or on fear-based messaging, have not been found effective and may be counterproductive.
Alanine (symbol Ala or A), or α-alanine, is an α-amino acid that is used in the biosynthesis of proteins. It contains an amine group and a carboxylic acid group, both attached to the central carbon atom which also carries a methyl group side chain. Consequently it is classified as a non-polar, aliphatic α-amino acid. Under biological conditions, alanine exists in its zwitterionic form with its amine group protonated (as −NH+3) and its carboxyl group deprotonated (as −CO−2). Alanine is encoded by all codons starting with GC (GCU, GCC, GCA, and GCG). The L-isomer of alanine (left-handed) is the one that is incorporated into proteins. L-alanine is second only to L-leucine in rate of occurrence, accounting for 7.8% of the primary structure in a sample of 1,150 proteins. The right-handed form, D-alanine, occurs in peptides in some bacterial cell walls (in peptidoglycan) and in some peptide antibiotics, and occurs in the tissues of many crustaceans and molluscs as an osmolyte. Alanine is not an essential amino acid in humans because it can be synthesized metabolically and does not need to be present in the diet. However hypoalaninemia (alanine deficiency) is possible under certain conditions such as ketotic hypoglycemia.
== External links == BetaTPred3 - Insilico platform for predicting and initiating betaturns in a protein at desired location Article Link NetTurnP - Prediction of Beta-turn regions in protein sequences BetaTPred - Prediction of Beta Turns in proteins using statistical algorithms
== Medical uses == Repotrectinib is indicated for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. In June 2024, the US Food and Drug Administration (FDA) expanded the indication to include the treatment of people twelve years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy.
=== Epitope databases === MHCBN: A database of MHC/TAP binder and T-cell epitopes Bcipep: A database of B-cell epitopes SYFPEITHI — First online database of T cell epitopes IEDB — Database of T and B cell epitopes with annotation of recognition context — NIH funded ANTIJEN — T and B cell epitope database at the Jenner institute, UK IMGT/3Dstructure-DB — Three-dimensional structures of B and T cell epitopes with annotation of IG and TR — IMGT, Montpellier, France SEDB: A Structural Epitope Database — Pondicheery University, DIT funded Epitopes at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.